{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:09:12Z","timestamp":1792649352387,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T00:00:00Z","timestamp":1579737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience & Biobehavioral Reviews"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.neubiorev.2020.01.017","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T16:23:34Z","timestamp":1579796614000},"page":"246-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"111","author":[{"given":"C.","family":"Okhuijsen-Pfeifer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.Y.","family":"Sterk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Terstappen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Luykx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.euroneuro.2017.02.005","article-title":"Clozapine as the most efficacious antipsychotic for activating ERK 1\/2 kinases: role of 5-HT2A receptor agonism","volume":"27","author":"Aringhieri","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0010","series-title":"Introduction to Meta-analysis","first-page":"45","article-title":"Chapter 7: converting among effect sizes","author":"Borenstein","year":"2009"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.151.1.20","article-title":"Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia","volume":"151","author":"Breier","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2020.01.017_bib0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/JCP.0000000000000734","article-title":"Clozapine use in a cohort of first-episode psychosis","volume":"37","author":"Doyle","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/394896","article-title":"Randomized Controlled Trial of Clozapine and CBT for First-Episode Psychosis with Enduring Positive Symptoms: a Pilot Study","author":"Edwards","year":"2011","journal-title":"Schizophr. Res. Treatment"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia","volume":"7","author":"Falkai","year":"2006","journal-title":"World J. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1192\/bjp.bp.110.088690","article-title":"Clozapine: Dangerous orphan or neglected friend?","volume":"198","author":"Farooq","year":"2011","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.neubiorev.2020.01.017_bib0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archpsyc.1991.01810350009002","article-title":"Natural history of schizophrenia subtypes: I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia","volume":"48","author":"Fenton","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/acps.12193","article-title":"Practitioner attitudes to clozapine initiation","volume":"130","author":"Gee","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0050","series-title":"ECDEU Assessment Manual for Psychopharmacology-Revised","article-title":"Clinical Global Impression (CGI)","author":"Guy","year":"1976"},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0055","series-title":"ECDEU Assesment Manual for Psychopharmacology","first-page":"218","article-title":"Clinical Global Impression","author":"Guy","year":"1976"},{"issue":"10","key":"10.1016\/j.neubiorev.2020.01.017_bib0060","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.npp.1301147","article-title":"Linking the PANSS, BPRS, and CGI: clinical implications","volume":"31","author":"Hamann","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0065","first-page":"43","volume":"6","author":"Harvey","year":"2009"},{"issue":"7414","key":"10.1016\/j.neubiorev.2020.01.017_bib0070","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.neubiorev.2020.01.017_bib0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00023210-199911040-00007","article-title":"Predicting response to clozapine: status of current research","volume":"11","author":"Hu","year":"1999","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0085","first-page":"1","article-title":"Schizophrenia","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"9","key":"10.1016\/j.neubiorev.2020.01.017_bib0090","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozaril collaborative study group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.neubiorev.2020.01.017_bib0095","first-page":"5","article-title":"Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2020.01.017_bib0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","article-title":"The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009","volume":"36","author":"Kreyenbuhl","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0110","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application","volume":"75","author":"Leucht","year":"2014","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.neubiorev.2020.01.017_bib0120","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl B","key":"10.1016\/j.neubiorev.2020.01.017_bib0125","first-page":"126","article-title":"Predictors of response to clozapine","volume":"55","author":"Lieberman","year":"1994","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.neubiorev.2020.01.017_bib0130","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatmentnaive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.neubiorev.2020.01.017_bib0135","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2020.01.017_bib0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","article-title":"A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia","volume":"69","author":"Meltzer","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0145","series-title":"The nice guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. updated edtition","author":"National Institute for Health & Clinical Excellence","year":"2010"},{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/acps.12954","article-title":"Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis","volume":"138","author":"Okhuijsen-Pfeifer","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.neubiorev.2020.01.017_bib0155","doi-asserted-by":"crossref","first-page":"e01318","DOI":"10.1002\/brb3.1318","article-title":"Differences between physicians\u2019 and nurse practitioners\u2019 viewpoints on reasons for clozapine underprescription","volume":"9","author":"Okhuijsen-Pfeifer","year":"2019","journal-title":"Brain Behav."},{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0160","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/oxfordjournals.schbul.a033412","article-title":"How long to wait for a response to clozapine: a comparison of tune course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia","volume":"25","author":"Rosenheck","year":"1999","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.neubiorev.2020.01.017_bib0165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4103\/ijmr.IJMR_279_15","article-title":"Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: a pilot study","volume":"144","author":"Sahni","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpsyt.2018.00327","article-title":"Biological predictors of clozapine response: a systematic review","volume":"9","author":"Samanaite","year":"2018","journal-title":"Front. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.neubiorev.2020.01.017_bib0175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.schres.2013.07.003","article-title":"Randomized trial of clozapine vs. Risperidone in treatment-na\u00efve first-episode schizophrenia: results after one year","volume":"149","author":"Sanz-Fuentenebro","year":"2013","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0180","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.psychres.2011.12.047","article-title":"One-year functional outcomes of naturalistically treated patients with schizophrenia","volume":"98","author":"Spellmann","year":"2012","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0185","first-page":"167","article-title":"Schizofreniespectrum en andere psychotische stoornissen in de DSM-5The schizophrenia spectrum and other psychotic disorders in the DSM-5","volume":"56","author":"Tan","year":"2014","journal-title":"Tijdschr. Psychiatr."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/0253-7176.135365","article-title":"Schizophrenia and other psychotic disorders in diagnostic and statistical manual of mental disorders (DSM)-5: clinical implications of revisions from DSM-IV","volume":"36","author":"Tandon","year":"2014","journal-title":"Indian J. Psychol. Med."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4088\/JCP.v64n0107","article-title":"Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review","volume":"64","author":"Taylor","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.neubiorev.2020.01.017_bib0200","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"June","key":"10.1016\/j.neubiorev.2020.01.017_bib0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","article-title":"Prescriber and institutional barriers and facilitators of clozapine use: a systematic review","volume":"201","author":"Verdoux","year":"2018","journal-title":"Schizophr. Res."},{"issue":"11","key":"10.1016\/j.neubiorev.2020.01.017_bib0210","doi-asserted-by":"crossref","first-page":"e1460","DOI":"10.4088\/JCP.15m10047","article-title":"Effectiveness of antipsychotic drugs for 24-month maintenance treatment in first-episode schizophrenia: evidence from a community-based \u201creal-world\u201d study","volume":"77","author":"Zhang","year":"2016","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.neubiorev.2020.01.017_bib0215","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1177\/106002809302701016","article-title":"Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia","volume":"27","author":"Zito","year":"1993","journal-title":"Ann. Pharmacother."},{"issue":"Suppl 5","key":"10.1016\/j.neubiorev.2020.01.017_bib0220","doi-asserted-by":"crossref","first-page":"343s","DOI":"10.1016\/S0924-9338(97)83577-8","article-title":"Ten years\u2019 experience with clozapine in treatment-resistant schizophrenic patients: factors indicating the therapeutic response","volume":"12","author":"Alvarez","year":"1997","journal-title":"Eur. Psychiatry"},{"issue":"10","key":"10.1016\/j.neubiorev.2020.01.017_bib0225","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1176\/appi.ps.51.10.1249","article-title":"Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns","volume":"51","author":"Breier","year":"2000","journal-title":"Psychiatr. Serv."},{"issue":"6","key":"10.1016\/j.neubiorev.2020.01.017_bib0230","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/ajp.155.6.751","article-title":"Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome","volume":"155","author":"Buchanan","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.neubiorev.2020.01.017_bib0235","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1176\/ajp.154.9.1243","article-title":"Time to clozapine response in a standardized trial","volume":"154","author":"Conley","year":"1997","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0006-3223(99)00029-3","article-title":"Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response","volume":"46","author":"Conley","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2020.01.017_bib0245","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0165-1781(93)90017-B","article-title":"Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia","volume":"46","author":"Davidson","year":"1993","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s002130000503","article-title":"Long-term therapeutic drug monitoring of clozapine and metabolites psychiatric in- and outpatients","volume":"152","author":"Dettling","year":"2000","journal-title":"Psychopharmacol. (Berl.)"},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0255","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0893-133X(02)00319-6","article-title":"Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia","volume":"27","author":"Fabrazzo","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00005053-199301000-00013","article-title":"Can clozapine response be predicted? A naturalistic pilot study","volume":"181","author":"Fenton","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"issue":"6","key":"10.1016\/j.neubiorev.2020.01.017_bib0265","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00004714-199312000-00003","article-title":"Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia","volume":"13","author":"Hasegawa","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0270","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00004850-199705000-00001","article-title":"A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia","volume":"12","author":"Hong","year":"1997","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0275","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.comppsych.2009.07.003","article-title":"Nonresponse to clozapine and premorbid functioning in treatment refractory schizophrenia","volume":"51","author":"Kelly","year":"2010","journal-title":"Compr. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0280","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/JCP.0b013e31827d14e3","article-title":"Effects of clozapine on heart rate dynamics and their relationship with therapeutic response in treatment-resistant schizophrenia","volume":"33","author":"Kim","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0285","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.schres.2017.05.040","article-title":"Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment","volume":"192","author":"Krivoy","year":"2018","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0290","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/YIC.0b013e3283277627","article-title":"Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients","volume":"24","author":"Lee","year":"2009","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0295","first-page":"30","article-title":"Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations","volume":"27","author":"Llorca","year":"2002","journal-title":"J. Psychiatry Neurosci."},{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0300","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1176\/jnp.11.4.481","article-title":"Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia","volume":"11","author":"Manschreck","year":"1999","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.neubiorev.2020.01.017_bib0305","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/01.jcp.0000095351.32154.3a","article-title":"Predictors of clinical outcome in schizophrenic patients responding to clozapine","volume":"23","author":"Mauri","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-3223(98)00377-1","article-title":"Smoking and therapeutic response to clozapine in patients with schizophrenia","volume":"46","author":"McEvoy","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"Supplement 1","key":"10.1016\/j.neubiorev.2020.01.017_bib0315","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1007\/BF00442563","article-title":"A prospective study of clozapine in treatment-resistant schizophrenic patients - I. Preliminary report","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1590\/S1516-44462007000300007","article-title":"Clinical aspects of super-refractory schizophrenia: A 6-month cohort observational study","volume":"29","author":"Neto","year":"2007","journal-title":"Rev. Bras. Psiquiatr."},{"issue":"4","key":"10.1016\/j.neubiorev.2020.01.017_bib0325","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1590\/1516-4446-2013-1190","article-title":"Is disorganized schizophrenia a predictor of treatment resistance? Evidence from an observational study","volume":"35","author":"Ortiz","year":"2013","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.neubiorev.2020.01.017_bib0330","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1192\/bjp.141.6.567","article-title":"The evolution of symptoms in institutionalized hebephrenic\/catatonic schizophrenics","volume":"141","author":"Pfohl","year":"1982","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.neubiorev.2020.01.017_bib0335","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0340","first-page":"51","article-title":"Clinical predictors of response to clozapine in patients with treatment resistant schizophrenia","volume":"44","author":"Rajkumar","year":"2011","journal-title":"Psychopharmacol. Bull."},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0345","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-1781(97)00129-7","article-title":"Schizophrenic syndromes and clozapine response in treatment-resistant schizophrenia","volume":"77","author":"Rodriguez","year":"1998","journal-title":"Psychiatry Res."},{"issue":"6","key":"10.1016\/j.neubiorev.2020.01.017_bib0350","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.pnpbp.2007.06.002","article-title":"Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia","volume":"31","author":"Semiz","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neubiorev.2020.01.017_bib0355","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s002130050028","article-title":"Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics","volume":"148","author":"Spina","year":"2000","journal-title":"Psychopharmacol. (Berl.)"},{"issue":"12","key":"10.1016\/j.neubiorev.2020.01.017_bib0360","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1176\/ajp.151.12.1817","article-title":"Early response to clozapine in schizophrenia","volume":"151","author":"Stern","year":"1994","journal-title":"Am. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2020.01.017_bib0365","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0165-1781(96)02993-9","article-title":"Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine","volume":"69","author":"Sumiyoshi","year":"1997","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.neubiorev.2020.01.017_bib0370","first-page":"51","article-title":"Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia","volume":"44","author":"Umbricht","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.neubiorev.2020.01.017_bib0375","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2006.01.011","article-title":"Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia","volume":"83","author":"Xiang","year":"2006","journal-title":"Schizophr. Res."}],"container-title":["Neuroscience & Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763419310164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763419310164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T16:24:38Z","timestamp":1722356678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763419310164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":75,"alternative-id":["S0149763419310164"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2020.01.017","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2020.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}